Dose-intensified rechallenge with temozolomide: One week on/one week off versus 3 weeks on/one week off in patients with progressive or recurrent glioblastoma (DIRECTOR).
Ghazaleh Tabatabai
Honoraria - Merck Sharp & Dohme; Roche
Wolfgang Wick
Consultant or Advisory Role - MSD; Roche
Honoraria - MSD; Roche
Research Funding - Apogenix; Boehringer Ingelheim; MSD; Roche
Guido Reifenberger
Honoraria - MSD; Roche
Joachim Peter Steinbach
Consultant or Advisory Role - Roche
Research Funding - Merck Serono
Oliver Schnell
No relevant relationships to disclose
Peter Hau
Consultant or Advisory Role - MSD
Ulrich Herrlinger
Honoraria - Medac
Research Funding - Medac
Michael Sabel
No relevant relationships to disclose
Ralf Ketter
No relevant relationships to disclose
Uwe S. Schlegel
Consultant or Advisory Role - MSD
Honoraria - MSD
Christine Marosi
No relevant relationships to disclose
Roland Goldbrunner
No relevant relationships to disclose
Krisztian Homicsko
No relevant relationships to disclose
Guido Nikkhah
No relevant relationships to disclose
Josef Pichler
Honoraria - MSD
Peter Vajkoczy
No relevant relationships to disclose
Juergen Meixensberger
No relevant relationships to disclose
Michael Weller
Consultant or Advisory Role - Antisense Pharma; MSD; Roche
Research Funding - Antisense Pharma; Bayer; MSD; Roche